Literature DB >> 26391553

Clinical significance of preoperative platelet-to-lymphocyte ratio in recurrent hepatocellular carcinoma after thermal ablation: A retrospective analysis.

Xin Li1,2, Zhiyu Han1, Zhigang Cheng1, Jie Yu1, Xiaoling Yu1, Ping Liang1.   

Abstract

PURPOSE: The aim of this study was to elucidate the clinical significance of preoperative Platelet-to-lymphocyte ratio (PLR) in recurrent hepatocellular carcinoma (RHCC) patients after thermal ablation.
MATERIALS AND METHODS: We retrospectively reviewed 414 patients with  RHCC treated with ultrasound-guided thermal ablation percutaneously between January 2010 and March 2014. The correlation of recurrence-free survival (RFS) with 15 clinical parameters was analysed by Cox multivariate proportional hazard model analysis. The best cut-off value of preoperative PLR was determined with time-dependent receiver operating characteristic (ROC) curve analysis. The value of PLR in predicting recurrence was analysed by Kaplan-Meier.
RESULTS: Multivariate Cox proportional hazard model analysis showed that tumour differentiation, prothrombin time (PT), absolute lymphocyte count (ALC) and PLR were risk factors for recurrence in RHCC patients. PLR ≥ 87.87 was considered for evaluation (AUROC = 0.667; P < 0.05), and 166 of 414 patients (40.1%) had PLR of more than 87.87. During the follow-up period (12-52 months), the 1- and 3-year recurrence rates were 39.9% and 54.8% in the low PLR group, which were significantly better than those in the high PLR group (56.0% and 79.5%) (P < 0.05). Kaplan-Meier analysis demonstrated that the RFS in the low PLR group was 45.2% which was significantly higher than that of the high PLR group (20.5%) (X2 = 24.019, P < 0.05). This result suggested that preoperative PLR is a predictor for recurrence followed thermal ablation in RHCC patients, and patients with PLR ≥ 87.87 indicated higher RFS, which may improve the clinical management of RHCC patients. Further studies are warranted to validated this finding and test its clinical applicability in RHCC.

Entities:  

Keywords:  Platelet-to-lymphocyte ratio (PLR); recurrence-free survival (RFS); recurrent hepatocellular carcinoma (RHCC); thermal ablation

Mesh:

Year:  2015        PMID: 26391553     DOI: 10.3109/02656736.2015.1068958

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  7 in total

1.  The Lymphocyte-Monocyte Ratio and the Platelet-Lymphocyte Ratio at Diagnosis as Independent Prognostic Factors in Primary Gastrointestinal Diffuse Large B Cell Lymphoma.

Authors:  Pan Zhao; Li Zang; Xiaoying Zhang; Yafang Chen; Hongliang Yang; Haifeng Zhao; Yong Yu; Yafei Wang; Yizhuo Zhang; Xiaofang Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2016-08-29       Impact factor: 0.900

2.  Hepatocellular Carcinoma Within the Milan Criteria: A Novel Inflammation-Based Nomogram System to Assess the Outcomes of Ablation.

Authors:  Shuanggang Chen; Weimei Ma; Fei Cao; Lujun Shen; Han Qi; Lin Xie; Ying Wu; Weijun Fan
Journal:  Front Oncol       Date:  2020-09-14       Impact factor: 6.244

3.  Novel prognostic scoring system for diffuse large B-cell lymphoma.

Authors:  Pan Zhao; Li Zang; Xiaoying Zhang; Yafang Chen; Zhijie Yue; Hongliang Yang; Haifeng Zhao; Yong Yu; Yafei Wang; Zhigang Zhao; Yizhuo Zhang; Xiaofang Wang
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

4.  Platelet-to-lymphocyte ratio could be a promising prognostic biomarker for survival of colorectal cancer: a systematic review and meta-analysis.

Authors:  Hong-Xin Peng; Kang Lin; Bang-Shun He; Yu-Qin Pan; Hou-Qun Ying; Xiu-Xiu Hu; Tao Xu; Shu-Kui Wang
Journal:  FEBS Open Bio       Date:  2016-06-16       Impact factor: 2.693

5.  Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio.

Authors:  Weiliang Xia; Qinghong Ke; Hua Guo; Weilin Wang; Min Zhang; Yan Shen; Jian Wu; Xiao Xu; Sheng Yan; Jun Yu; Mangli Zhang; Shusen Zheng
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

Review 6.  Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Yongzhao Zhao; Guangyan Si; Fengshang Zhu; Jialiang Hui; Shangli Cai; Chenshen Huang; Sijin Cheng; Abdel Hamid Fathy; Yi Xiang; Jing Li
Journal:  Oncotarget       Date:  2017-04-04

Review 7.  Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma.

Authors:  Wei Song; Kai Wang; Fu-Ping Zhong; You-Wen Fan; Lang Peng; Shu-Bing Zou
Journal:  Oncotarget       Date:  2016-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.